Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 10

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 10
---
 Technology Corporation (“UST”).
UST is dedicated to the development and commercialization of advanced proprietary DNA sequencing technologies. Paths Innovation Limited
currently holds, through its majority owned subsidiary Paths Diagnostics Pte. Limited, the PathsDx technology – a liquid biopsy
NGS based technology for the diagnostics of infectious diseases. As consideration for the Disposition, UST will issue such number of UST’s
shares to Aptorum Therapeutics valued at 18.75% of the combined business.

<div align='center'>S-3</div>

The
Disposition is subject to, among other things, the execution of a mutually agreeable definitive agreement, completion of due diligence,
respective directors, and shareholder approvals where relevant. There can be no assurance that a definitive agreement will be entered
into or that the proposed transaction will be consummated on the terms set forth herein or at all. Therefore, it is possible that the
Disposition may never occur.

The foregoing is only a brief description of the
Disposition and does not purport to be a complete description of the proposed terms of the Disposition and is qualified in its entirety
by reference to the Term Sheet and the definitive documents, if materialized.

At the Market Offering

On March 26, 2021, the Company
entered into an at the market offering agreement (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, acting
as our sales agent (the “Sales Agent”), relating to the sale of our Class A Ordinary Shares, offered pursuant to the prospectus
supplement and the accompanying prospectus to the registration statement on Form F-3 (File No. 333-268873) (such offering, the “ATM
Offering”, or “At The Market Offering”). In accordance with the terms of the Sales Agreement, as of the date of this
prospectus supplement, we may offer and sell shares of our Class A Ordinary Shares having an aggregate offering price of up to $1,552,575
from time to time through the Sales Agent under such prospectus supplement and the accompanying prospectus. As of the date of this prospectus
supplement, we have issued 215,959 Class A Ordinary Shares pursuant to the ATM Offering.

Nasdaq Deficiency Notice

As announced on a Form
6-K filed on May 5, 2023, the Company has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) Listing
Qualifications Department notifying the Company that it